---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008844"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:43:43.195728+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bio-Path presents positive Phase 2 prexigebersen data at ASCO; 75% CR/CRh/CRi in newly diagnosed AML

## Summary
- Cohort 1 (newly diagnosed AML): 75% of evaluable patients (15/20) achieved CR/CRh/CRi; median age 75 yrs, adverse-risk or sAML.
- Cohort 2 (relapsed/refractory AML): 55% of evaluable patients (12/23) achieved CR/CRi/CRh; median age 63 yrs.
- Safety profile consistent with decitabine+venetoclax; common AEs: fatigue (72%), anemia (60%), neutropenia (49%).
- Bio-Path plans to continue enrollment up to 98 evaluable in Cohort 1 and 54 evaluable in Cohort 2.
- Data presented as oral presentation at ASCO 2024 by MD Anderson investigator; CEO highlights unmet need.

## SEC filing metadata
- accession: 0001558370-24-008844
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024008844/0001558370-24-008844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024008844/bpth-20240603x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008844
- JSON: https://secwatch.observer/filing/0001558370-24-008844.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008844.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.